AbbVie (ABBV) and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to AbbVie (ABBV) and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

July 26, 2023 9:00 AM EDT

NORTH CHICAGO, Ill. and LA JOLLA, Calif., July 26, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest. This partnership is an expansion of the collaboration AbbVie and Scripps Research... More